Charles Flexner
MD
Johns Hopkins University School of Medicine, United States
International Workshop on Monoclonal Antibodies for Treatment & Prevention of Infectious Diseases 2023
What's New
- To stay updated on the relevant developments, make sure you are signed up for our newsletter.
Welcome
With more than 100 monoclonal antibiotics (mAbs) in use, harnessing this technology has advanced therapeutic development for COVID-19 and underscored their utility and versatility to respond rapidly to emerging global health threats.
Recent approvals and recommendations for mAbs in preventing and treating RSV and Ebola offer novel tools to control these (re) emerging viruses.
They also offer new avenues for preventing bacterial and parasitic infections, such as Clostridium difficile and Plasmodium falciparum (causative agent of malaria tropica in humans).
Those advances come hand-in-hand with educational needs to comprehend technology, pharmacological properties, challenges for equitable access, and recent clinical data.
In contrast to existing programs, this workshop provided a platform for cross-disciplinary discussion, catalyzed knowledge transfer, and prompted the discussions on remaining unknowns to ultimately move the field forward.
Program Directors
Daniel Kuritzkes
MD
Brigham and Women's Hospital / Harvard Medical School, United States